

REMARKS

Claims 1-6, 8, 13, 16, 17 and 22 stand rejected. With entry of this amendment, claims 1-6, 8, 13, 16, 17 and 22 are pending and claims 1, 3, 5, 6, 8, 16 and 17 are amended.

Claim Rejections – 35 USC § 101

Claim 16 has been amended to overcome this rejection.

Claim Rejections – 35 USC § 112

Claims 8 and 17 are now directed to a composition comprising the peptide of claim 1 and a pharmaceutical excipient, thereby overcoming this rejection. Claims 11 and 20 have been canceled, rendering this rejection moot.

With respect to the rejection for indefiniteness for claims 2 and 4, applicants state that SEQ ID NOS: 50-59 and SEQ ID NOS: 65-88 are sub-genera of the genus of SEQ ID NO: 9. Claims 3 and 5 have been amended to add the phrase SEQ ID NOS for SEQ ID NOS: 60-64 and SEQ ID NOS 89-96.


Claim Rejections – 35 USC § 102

Applicants have removed the open language describing the structure of the peptides thereby overcoming the rejection for anticipation by Gobron.

Respectfully submitted,

Date October 20, 2004

FOLEY & LARDNER LLP
Customer Number: 22428
Telephone: (202) 672-5300
Facsimile: (202) 672-5399



Matthew E. Mulkeen
Attorney for Applicants
Registration No. 44,250

Should additional fees be necessary in connection with the filing of this paper, or if a petition for extension of time is required for timely acceptance of same, the Commissioner is hereby authorized to charge Deposit Account No. 19-0741 for any such fees; and applicant(s) hereby petition for any needed extension of time.